BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), today announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against the Omicron variant as well as additional data from its ongoing Phase 2 boost study.

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.

Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced full results from a Phase 3 investigational study evaluating the efficacy and safety of a three-day course of Veklury® (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression.

Biophytis SA announces the issuance of the last 120 Bonds Redeemable in Cash and New and Existing Shares for a total amount of €3 million under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York for €24 million.

Researchers from Intermountain Healthcare played a key role in a new international study that has found that an antiviral drug designed to inhibit the ability of the SARS-CoV-2 virus to reproduce itself is effective at preventing severe illness from COVID when given early in the symptom course.

Aerogen Pharma, and Nuance Pharma (“Nuance”), today announce an exclusive agreement to join forces in Greater China to develop a superior, non-invasive approach to treatment of RDS, a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.

Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in patients four years and older, and active psoriatic arthritis (PsA) in patients two years and older.

The global smart medical devices market is likely to witness growth at a CAGR of 7.8% during the forecast period of 2016 to 2024, according to the analysts of a new research report by Transparency Market Research.

Pfizer Inc. announced an additional agreement with the United Kingdom government to supply an additional 2.5 million treatment courses of its investigational candidate PAXLOVID™, subject to local authorization.